SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

BioRestorative Therapies, Inc. – ‘10-Q’ for 9/30/23 – ‘XML’

On:  Monday, 11/13/23, at 4:06pm ET   ·   For:  9/30/23   ·   Accession #:  1493152-23-40483   ·   File #:  1-37603

Previous ‘10-Q’:  ‘10-Q’ on 8/11/23 for 6/30/23   ·   Latest ‘10-Q’:  This Filing   ·   2 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/13/23  BioRestorative Therapies, Inc.    10-Q        9/30/23   50:3.6M                                   M2 Compliance LLC/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    754K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     21K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     21K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     17K 
10: R1          Cover                                               HTML     70K 
11: R2          Condensed Consolidated Balance Sheets               HTML    100K 
12: R3          Condensed Consolidated Balance Sheets               HTML     37K 
                (Parenthetical)                                                  
13: R4          Condensed Consolidated Statements of Operations     HTML     75K 
                (Unaudited)                                                      
14: R5          Condensed Consolidated Statements of Changes in     HTML    101K 
                Stockholders' Equity (Unaudited)                                 
15: R6          Condensed Consolidated Statements of Cash Flows     HTML     80K 
                (Unaudited)                                                      
16: R7          Nature of the Organization, Liquidity, and          HTML     33K 
                Business                                                         
17: R8          Basis of Presentation and Summary of Significant    HTML     65K 
                Accounting Policies                                              
18: R9          Intangible Assets                                   HTML     41K 
19: R10         Accrued Expenses and Other Current Liabilities      HTML     23K 
20: R11         Stockholders? Equity                                HTML     91K 
21: R12         Leases                                              HTML     35K 
22: R13         Subsequent Events                                   HTML     22K 
23: R14         Basis of Presentation and Summary of Significant    HTML     79K 
                Accounting Policies (Policies)                                   
24: R15         Basis of Presentation and Summary of Significant    HTML     46K 
                Accounting Policies (Tables)                                     
25: R16         Intangible Assets (Tables)                          HTML     39K 
26: R17         Accrued Expenses and Other Current Liabilities      HTML     21K 
                (Tables)                                                         
27: R18         Stockholders? Equity (Tables)                       HTML     61K 
28: R19         Leases (Tables)                                     HTML     32K 
29: R20         Nature of the Organization, Liquidity, and          HTML     53K 
                Business (Details Narrative)                                     
30: R21         Schedule of Fair Value Recurring Basis (Details)    HTML     24K 
31: R22         Schedule of Weighted Average Dilutive Common        HTML     30K 
                Shares (Details)                                                 
32: R23         Basis of Presentation and Summary of Significant    HTML     17K 
                Accounting Policies (Details Narrative)                          
33: R24         Schedule of Intangible Assets (Details)             HTML     36K 
34: R25         Schedule of Intangible Assets Amortization          HTML     29K 
                Expenses (Details)                                               
35: R26         Intangible Assets (Details Narrative)               HTML     21K 
36: R27         Schedule of Accrued Expenses and Other Current      HTML     22K 
                Liabilities (Details)                                            
37: R28         Schedule of Stock Option Granted Assumptions        HTML     27K 
                (Details)                                                        
38: R29         Schedule of Stock Option Activity (Details)         HTML     41K 
39: R30         Schedule of Unvested Restricted Stock Units         HTML     35K 
                (Details)                                                        
40: R31         Schedule of Stock Compensation by Award Type        HTML     34K 
                (Details)                                                        
41: R32         Stockholders? Equity (Details Narrative)            HTML    109K 
42: R33         Schedule of Net Lease Cost and Other Supplemental   HTML     31K 
                Lease Information (Details)                                      
43: R34         Schedule of Future Minimum Payments Under           HTML     26K 
                Non-Cancelable Leases for Operating Leases                       
                (Details)                                                        
44: R35         Leases (Details Narrative)                          HTML     27K 
45: R36         Subsequent Events (Details Narrative)               HTML     36K 
48: XML         IDEA XML File -- Filing Summary                      XML     84K 
46: XML         XBRL Instance -- form10-q_htm                        XML    844K 
47: EXCEL       IDEA Workbook of Financial Report Info              XLSX     80K 
 6: EX-101.CAL  XBRL Calculations -- brtx-20230930_cal               XML    108K 
 7: EX-101.DEF  XBRL Definitions -- brtx-20230930_def                XML    307K 
 8: EX-101.LAB  XBRL Labels -- brtx-20230930_lab                     XML    598K 
 9: EX-101.PRE  XBRL Presentations -- brtx-20230930_pre              XML    479K 
 5: EX-101.SCH  XBRL Schema -- brtx-20230930                         XSD     75K 
49: JSON        XBRL Instance as JSON Data -- MetaLinks              281±   402K 
50: ZIP         XBRL Zipped Folder -- 0001493152-23-040483-xbrl      Zip    154K 


‘XML’   —   XBRL Instance — form10-q_htm


This Document is an XBRL File.


                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:BRTX="http://biorestorative.com/20230930" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:schemaRef xlink:href="brtx-20230930.xsd" xlink:type="simple"/>
<context id="From2023-01-01to2023-09-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="AsOf2023-11-10">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<instant> 2023-11-10 </instant>
</period>
</context>
<context id="AsOf2023-09-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2022-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-09-30_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="From2023-07-012023-09-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-03-31 </instant>
</period>
</context>
<context id="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-03-31 </instant>
</period>
</context>
<context id="AsOf2023-03-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-03-31 </instant>
</period>
</context>
<context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-03-31 </instant>
</period>
</context>
<context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-03-31 </instant>
</period>
</context>
<context id="AsOf2023-03-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<instant> 2023-03-31 </instant>
</period>
</context>
<context id="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-06-30 </instant>
</period>
</context>
<context id="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-06-30 </instant>
</period>
</context>
<context id="AsOf2023-06-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-06-30 </instant>
</period>
</context>
<context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-06-30 </instant>
</period>
</context>
<context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-06-30 </instant>
</period>
</context>
<context id="AsOf2023-06-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<instant> 2023-06-30 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2021-12-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<instant> 2021-12-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-03-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<instant> 2022-03-31 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="AsOf2022-06-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<instant> 2022-06-30 </instant>
</period>
</context>
<context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-03-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-03-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-03-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-03-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-03-31 </endDate>
</period>
</context>
<context id="From2023-01-012023-03-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-03-31 </endDate>
</period>
</context>
<context id="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-04-01 </startDate>
<endDate> 2023-06-30 </endDate>
</period>
</context>
<context id="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-04-01 </startDate>
<endDate> 2023-06-30 </endDate>
</period>
</context>
<context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-04-01 </startDate>
<endDate> 2023-06-30 </endDate>
</period>
</context>
<context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-04-01 </startDate>
<endDate> 2023-06-30 </endDate>
</period>
</context>
<context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-04-01 </startDate>
<endDate> 2023-06-30 </endDate>
</period>
</context>
<context id="From2023-04-012023-06-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<startDate> 2023-04-01 </startDate>
<endDate> 2023-06-30 </endDate>
</period>
</context>
<context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-01-012022-03-31">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-03-31 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-04-012022-06-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<startDate> 2022-04-01 </startDate>
<endDate> 2022-06-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2023-09-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesAConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2022-09-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<instant> 2022-09-30 </instant>
</period>
</context>
<context id="AsOf2023-04-14_custom_JonesTradingInstitutionalServicesLLCMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> BRTX:JonesTradingInstitutionalServicesLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-04-14 </instant>
</period>
</context>
<context id="From2023-04-132023-04-14_custom_JonesTradingInstitutionalServicesLLCMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> BRTX:JonesTradingInstitutionalServicesLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-04-13 </startDate>
<endDate> 2023-04-14 </endDate>
</period>
</context>
<context id="From2023-07-122023-07-13">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<startDate> 2023-07-12 </startDate>
<endDate> 2023-07-13 </endDate>
</period>
</context>
<context id="AsOf2023-07-13">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<instant> 2023-07-13 </instant>
</period>
</context>
<context id="AsOf2023-09-30_us-gaap_FairValueInputsLevel1Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2023-09-30_us-gaap_FairValueInputsLevel2Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2023-09-30_us-gaap_FairValueInputsLevel3Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel3Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel1Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel2Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis"> us-gaap:FairValueInputsLevel3Member </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2023-07-012023-09-30_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2023-07-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2023-07-012023-09-30_us-gaap_ConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:ConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_ConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:ConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-09-30_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-09-30_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-09-30_us-gaap_ConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:ConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_us-gaap_ConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> us-gaap:ConvertiblePreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-11-012022-11-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
</entity>
<period>
<startDate> 2022-11-01 </startDate>
<endDate> 2022-11-30 </endDate>
</period>
</context>
<context id="AsOf2022-11-30_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-11-30 </instant>
</period>
</context>
<context id="From2022-11-012022-11-30_us-gaap_WarrantMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-11-01 </startDate>
<endDate> 2022-11-30 </endDate>
</period>
</context>
<context id="AsOf2022-12-31_custom_PatentsAndTrademarksMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> BRTX:PatentsAndTrademarksMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_LicensesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> BRTX:LicensesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_AccumulatedAmortizationMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> BRTX:AccumulatedAmortizationMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="From2023-01-012023-09-30_custom_PatentsAndTrademarksMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> BRTX:PatentsAndTrademarksMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-09-30_custom_LicensesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> BRTX:LicensesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-09-30_custom_AccumulatedAmortizationMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> BRTX:AccumulatedAmortizationMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="AsOf2023-09-30_custom_PatentsAndTrademarksMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> BRTX:PatentsAndTrademarksMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2023-09-30_custom_LicensesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> BRTX:LicensesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2023-09-30_custom_AccumulatedAmortizationMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> BRTX:AccumulatedAmortizationMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2022-12-31_custom_PatentsAndTrademarkMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> BRTX:PatentsAndTrademarkMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_LicenseMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:LicenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="From2023-01-012023-09-30_custom_PatentsAndTrademarkMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> BRTX:PatentsAndTrademarkMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-09-30_us-gaap_LicenseMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:LicenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="AsOf2023-09-30_custom_PatentsAndTrademarkMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> BRTX:PatentsAndTrademarkMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2023-09-30_us-gaap_LicenseMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis"> us-gaap:LicenseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-11-08 </instant>
</period>
</context>
<context id="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-09-08 </instant>
</period>
</context>
<context id="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-09-08 </startDate>
<endDate> 2022-09-08 </endDate>
</period>
</context>
<context id="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesAPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-09-08 </startDate>
<endDate> 2022-09-08 </endDate>
</period>
</context>
<context id="From2023-01-012023-09-30_us-gaap_SeriesBPreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="AsOf2023-09-30_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"> BRTX:BeneficialOwnershipMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="From2023-01-012023-09-30_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"> BRTX:BeneficialOwnershipMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:SeriesBPreferredStockMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> BRTX:SeriesBConvertiblePreferredStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> BRTX:AuctusFundLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-04-03 </startDate>
<endDate> 2023-04-04 </endDate>
</period>
</context>
<context id="From2023-04-032023-04-04_custom_AuctusFundLLCMember_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> BRTX:AuctusFundLLCMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-04-03 </startDate>
<endDate> 2023-04-04 </endDate>
</period>
</context>
<context id="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> BRTX:TwoThousandTwentyOneStockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-03-18 </instant>
</period>
</context>
<context id="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> BRTX:TwoThousandTwentyOneStockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-10 </instant>
</period>
</context>
<context id="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> BRTX:TwoThousandTwentyOneStockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2021-12-10 </instant>
</period>
</context>
<context id="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> BRTX:TwoThousandTwentyOneStockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-07-13 </instant>
</period>
</context>
<context id="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> BRTX:TwoThousandTwentyOneStockIncentivePlanMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-07-13 </instant>
</period>
</context>
<context id="From2023-01-012023-09-30_us-gaap_StockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> us-gaap:StockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_us-gaap_StockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis"> us-gaap:StockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2022-12-31 </instant>
</period>
</context>
<context id="From2023-01-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember37226718">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="AsOf2023-09-30_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember37226828">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_EmployeeStockOptionMember37226828">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2023-07-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember37226828">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember37226843">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2023-07-012023-09-30_custom_SharesIssuedForServicesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> BRTX:SharesIssuedForServicesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-07-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-07-012022-09-30_custom_SharesIssuedForServicesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> BRTX:SharesIssuedForServicesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-07-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-09-30_us-gaap_EmployeeStockOptionMember37226859">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember37226859">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:EmployeeStockOptionMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember37226875">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> us-gaap:RestrictedStockUnitsRSUMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-09-30_custom_SharesIssuedForServicesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> BRTX:SharesIssuedForServicesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2022-01-012022-09-30_custom_SharesIssuedForServicesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> BRTX:SharesIssuedForServicesMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2022-01-01 </startDate>
<endDate> 2022-09-30 </endDate>
</period>
</context>
<context id="AsOf2023-09-30_custom_MelvilleLeaseMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> BRTX:MelvilleLeaseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-09-30 </instant>
</period>
</context>
<context id="From2023-01-012023-09-30_custom_MelvilleLeaseMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> BRTX:MelvilleLeaseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2023-01-012023-09-30_custom_MelvilleLeaseMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> BRTX:MelvilleLeaseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-01-01 </startDate>
<endDate> 2023-09-30 </endDate>
</period>
</context>
<context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> BRTX:MelvilleLeaseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-06-01 </startDate>
<endDate> 2019-06-30 </endDate>
</period>
</context>
<context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> BRTX:MelvilleLeaseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-06-01 </startDate>
<endDate> 2019-06-30 </endDate>
</period>
</context>
<context id="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis"> BRTX:MelvilleLeaseMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2019-06-01 </startDate>
<endDate> 2019-06-30 </endDate>
</period>
</context>
<context id="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_DemandSalesAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis"> BRTX:DemandSalesAgreementMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-04-01 </startDate>
<endDate> 2023-04-30 </endDate>
</period>
</context>
<context id="From2023-10-012023-10-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate> 2023-10-01 </startDate>
<endDate> 2023-10-31 </endDate>
</period>
</context>
<context id="AsOf2023-10-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK"> 0001505497 </identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant> 2023-10-31 </instant>
</period>
</context>
<unit id="USD">
<measure> iso4217:USD </measure>
</unit>
<unit id="Shares">
<measure> shares </measure>
</unit>
<unit id="USDPShares">
<divide>
<unitNumerator>
<measure> iso4217:USD </measure>
</unitNumerator>
<unitDenominator>
<measure> shares </measure>
</unitDenominator>
</divide>
</unit>
<unit id="sqft">
<measure> utr:sqft </measure>
</unit>
<unit id="Pure">
<measure> pure </measure>
</unit>
<dei:AmendmentFlag contextRef="From2023-01-01to2023-09-30"> false </dei:AmendmentFlag>
<dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-09-30"> Q3 </dei:DocumentFiscalPeriodFocus>
<dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-09-30"> --12-31 </dei:CurrentFiscalYearEndDate>
<dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-09-30"> 0001505497 </dei:EntityCentralIndexKey>
<BRTX:GainOnPppLoanForgiveness contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0205" unitRef="USD" xsi:nil="true"/>
<BRTX:GainOnPppLoanForgiveness contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0206" unitRef="USD" xsi:nil="true"/>
<BRTX:GainOnPppLoanForgiveness contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0207" unitRef="USD" xsi:nil="true"/>
<BRTX:GrantIncome contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0211" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0262" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0269" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0282" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0283" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0286" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0291" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0292" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0293" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0295" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0298" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0299" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0300" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0301" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0302" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-01-012023-03-31" id="xdx2ixbrl0303" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0305" unitRef="Shares" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0307" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0308" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0309" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0310" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0314" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0321" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0334" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0335" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0336" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0338" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0343" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0344" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0345" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0347" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0350" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0351" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0352" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0353" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0354" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0355" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0357" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0358" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0361" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0366" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0370" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2023-04-012023-06-30" id="xdx2ixbrl0371" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0377" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0378" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0379" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0380" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0384" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0391" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0404" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0405" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0406" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0408" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0411" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0418" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0423" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2023-07-012023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0434" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0441" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0448" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0455" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0463" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0474" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0475" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0478" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0483" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0484" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0485" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0487" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0490" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0491" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0494" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0499" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0500" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0501" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0502" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0507" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0515" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0526" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0527" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0530" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0535" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0536" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0537" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0539" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0542" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0543" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0544" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0546" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0551" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0552" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0553" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0554" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0559" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0567" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0572" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0580" unitRef="Shares" xsi:nil="true"/>
<BRTX:StockIssuedDuringPeriodValueExchange contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0586" unitRef="USD" xsi:nil="true"/>
<BRTX:StockIssuedDuringPeriodValueExchange contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0587" unitRef="USD" xsi:nil="true"/>
<BRTX:StockIssuedDuringPeriodValueExchange contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0588" unitRef="USD" xsi:nil="true"/>
<BRTX:StockIssuedDuringPeriodValueExchange contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0589" unitRef="USD" xsi:nil="true"/>
<BRTX:StockIssuedDuringPeriodSharesExchange contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0595" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0604" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0605" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0606" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0608" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0613" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0614" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0615" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0617" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0620" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0621" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0622" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0623" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0624" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0625" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0629" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0630" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0631" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0632" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0636" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0643" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0649" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0656" unitRef="Shares" xsi:nil="true"/>
<BRTX:GainOnPppLoanForgiveness contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0680" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0711" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0726" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0732" unitRef="USD" xsi:nil="true"/>
<us-gaap:AssetsFairValueDisclosure contextRef="AsOf2023-09-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0785" unitRef="USD" xsi:nil="true"/>
<us-gaap:AssetsFairValueDisclosure contextRef="AsOf2023-09-30_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0787" unitRef="USD" xsi:nil="true"/>
<us-gaap:AssetsFairValueDisclosure contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0793" unitRef="USD" xsi:nil="true"/>
<us-gaap:AssetsFairValueDisclosure contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0795" unitRef="USD" xsi:nil="true"/>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-07-012022-09-30_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0817" unitRef="Shares" xsi:nil="true"/>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-01-012022-09-30_us-gaap_ConvertiblePreferredStockMember" id="xdx2ixbrl0837" unitRef="Shares" xsi:nil="true"/>
<us-gaap:AmortizationOfIntangibleAssets contextRef="From2023-01-012023-09-30_custom_PatentsAndTrademarksMember" id="xdx2ixbrl0863" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfIntangibleAssets contextRef="From2023-01-012023-09-30_custom_LicensesMember" id="xdx2ixbrl0865" unitRef="USD" xsi:nil="true"/>
<us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="AsOf2023-09-30_custom_PatentsAndTrademarksMember" id="xdx2ixbrl0879" xsi:nil="true"/>
<us-gaap:AmortizationOfIntangibleAssets contextRef="From2023-01-012023-09-30_custom_PatentsAndTrademarkMember" id="xdx2ixbrl0891" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl1001" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl1003" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember37226718" id="xdx2ixbrl1021" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember37226718" id="xdx2ixbrl1023" unitRef="Shares" xsi:nil="true"/>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2023-07-012023-09-30_custom_SharesIssuedForServicesMember" id="xdx2ixbrl1039" unitRef="USD" xsi:nil="true"/>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2023-01-012023-09-30_custom_SharesIssuedForServicesMember" id="xdx2ixbrl1055" unitRef="USD" xsi:nil="true"/>
<dei:DocumentType contextRef="From2023-01-01to2023-09-30"> 10-Q </dei:DocumentType>
<dei:DocumentQuarterlyReport contextRef="From2023-01-01to2023-09-30"> true </dei:DocumentQuarterlyReport>
<dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-09-30"> 2023-09-30 </dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-09-30"> 2023 </dei:DocumentFiscalYearFocus>
<dei:DocumentTransitionReport contextRef="From2023-01-01to2023-09-30"> false </dei:DocumentTransitionReport>
<dei:EntityFileNumber contextRef="From2023-01-01to2023-09-30"> 001-37603 </dei:EntityFileNumber>
<dei:EntityRegistrantName contextRef="From2023-01-01to2023-09-30"> BIORESTORATIVE THERAPIES, INC. </dei:EntityRegistrantName>
<dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-09-30"> NV </dei:EntityIncorporationStateCountryCode>
<dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-09-30"> 30-1341024 </dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-09-30"> 40 Marcus Drive </dei:EntityAddressAddressLine1>
<dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-09-30"> Melville </dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-09-30"> NY </dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-09-30"> 11747 </dei:EntityAddressPostalZipCode>
<dei:CityAreaCode contextRef="From2023-01-01to2023-09-30"> (631) </dei:CityAreaCode>
<dei:LocalPhoneNumber contextRef="From2023-01-01to2023-09-30"> 760-8100 </dei:LocalPhoneNumber>
<dei:Security12bTitle contextRef="From2023-01-01to2023-09-30"> Common Stock, $0.0001 par value </dei:Security12bTitle>
<dei:TradingSymbol contextRef="From2023-01-01to2023-09-30"> BRTX </dei:TradingSymbol>
<dei:SecurityExchangeName contextRef="From2023-01-01to2023-09-30"> NASDAQ </dei:SecurityExchangeName>
<dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-09-30"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-09-30"> Yes </dei:EntityInteractiveDataCurrent>
<dei:EntityFilerCategory contextRef="From2023-01-01to2023-09-30"> Non-accelerated Filer </dei:EntityFilerCategory>
<dei:EntitySmallBusiness contextRef="From2023-01-01to2023-09-30"> true </dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-09-30"> false </dei:EntityEmergingGrowthCompany>
<dei:EntityShellCompany contextRef="From2023-01-01to2023-09-30"> false </dei:EntityShellCompany>
<dei:EntityBankruptcyProceedingsReportingCurrent contextRef="From2023-01-01to2023-09-30"> true </dei:EntityBankruptcyProceedingsReportingCurrent>
<dei:EntityCommonStockSharesOutstanding contextRef="AsOf2023-11-10" decimals="INF" unitRef="Shares"> 4706917 </dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 2436869 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 1676577 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 9801837 </us-gaap:MarketableSecuritiesCurrent>
<us-gaap:MarketableSecuritiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 13072831 </us-gaap:MarketableSecuritiesCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 39300 </us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 16000 </us-gaap:AccountsReceivableNetCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 325931 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 363082 </us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 12603937 </us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 15128490 </us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 306310 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 261003 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 154726 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 241760 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 736128 </us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 803438 </us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:Assets contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 13801101 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 16434691 </us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 227355 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 170902 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 548954 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 130072 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 156310 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 139328 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:LiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 932619 </us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 440302 </us-gaap:LiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 42414 </us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 162317 </us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:Liabilities contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 975033 </us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 602619 </us-gaap:Liabilities>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2023-09-30" decimals="INF" unitRef="USDPShares"> 0.01 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2022-12-31" decimals="INF" unitRef="USDPShares"> 0.01 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares"> 20000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares"> 20000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2023-09-30_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="USDPShares"> 0.01 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="USDPShares"> 0.01 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-09-30_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1543158 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1543158 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2023-09-30_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1398158 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-09-30_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1398158 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1518158 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1518158 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockValue contextRef="AsOf2023-09-30_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 13982 </us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 15182 </us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="AsOf2023-09-30_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 13982 </us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="AsOf2022-12-31_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 15182 </us-gaap:PreferredStockValue>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2023-09-30" decimals="INF" unitRef="USDPShares"> 0.0001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2022-12-31" decimals="INF" unitRef="USDPShares"> 0.0001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares"> 75000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares"> 75000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares"> 4667641 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares"> 4667641 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares"> 3677775 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares"> 3677775 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockValue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 468 </us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 369 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 177042781 </us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 168457418 </us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> -164231163 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> -152640897 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 12826068 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 15832072 </us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 13801101 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 16434691 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> 30700 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 29000 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 126500 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 116100 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> 874824 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 989170 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 3353960 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 2839731 </us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> 2260319 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 3649530 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 8772632 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 11568490 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> 3135143 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 4638700 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 12126592 </us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 14408221 </us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> -3104443 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> -4609700 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> -12000092 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> -14292121 </us-gaap:OperatingIncomeLoss>
<us-gaap:InterestIncomeExpenseNet contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> 61667 </us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> -28841 </us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 176070 </us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> -104465 </us-gaap:InterestIncomeExpenseNet>
<BRTX:GainOnPppLoanForgiveness contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 250000 </BRTX:GainOnPppLoanForgiveness>
<BRTX:GrantIncome contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> 83333 </BRTX:GrantIncome>
<BRTX:GrantIncome contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 83333 </BRTX:GrantIncome>
<BRTX:GrantIncome contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 16654 </BRTX:GrantIncome>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> 33951 </us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> -17284 </us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 150423 </us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> -17284 </us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> 178951 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> -46125 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 409826 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 144905 </us-gaap:NonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> -2925492 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> -4655825 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> -11590266 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> -14147216 </us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasic contextRef="From2023-07-012023-09-30" decimals="INF" unitRef="USDPShares"> -0.64 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="From2023-07-012023-09-30" decimals="INF" unitRef="USDPShares"> -0.64 </us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic contextRef="From2022-07-012022-09-30" decimals="INF" unitRef="USDPShares"> -1.28 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="From2022-07-012022-09-30" decimals="INF" unitRef="USDPShares"> -1.28 </us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic contextRef="From2023-01-01to2023-09-30" decimals="INF" unitRef="USDPShares"> -2.85 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="From2023-01-01to2023-09-30" decimals="INF" unitRef="USDPShares"> -2.85 </us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic contextRef="From2022-01-012022-09-30" decimals="INF" unitRef="USDPShares"> -3.93 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="From2022-01-012022-09-30" decimals="INF" unitRef="USDPShares"> -3.93 </us-gaap:EarningsPerShareDiluted>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2023-07-012023-09-30" decimals="INF" unitRef="Shares"> 4570843 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2023-07-012023-09-30" decimals="INF" unitRef="Shares"> 4570843 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2022-07-012022-09-30" decimals="INF" unitRef="Shares"> 3642215 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2022-07-012022-09-30" decimals="INF" unitRef="Shares"> 3642215 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2023-01-01to2023-09-30" decimals="INF" unitRef="Shares"> 4061975 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2023-01-01to2023-09-30" decimals="INF" unitRef="Shares"> 4061975 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2022-01-012022-09-30" decimals="INF" unitRef="Shares"> 3602979 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2022-01-012022-09-30" decimals="INF" unitRef="Shares"> 3602979 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:SharesOutstanding contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1518158 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 15182 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 3677775 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 369 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 168457418 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -152640897 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 15832072 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 89840 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 9 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1148750 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-01-012023-03-31" decimals="0" unitRef="USD"> 1148759 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 2190428 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-01-012023-03-31" decimals="0" unitRef="USD"> 2190428 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -5684222 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2023-01-012023-03-31" decimals="0" unitRef="USD"> -5684222 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1518158 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2023-03-31_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 15182 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 3767615 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 378 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 171796596 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -158325119 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD"> 13487037 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 1442 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1164135 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-04-012023-06-30" decimals="0" unitRef="USD"> 1164135 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 321534 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-04-012023-06-30" decimals="0" unitRef="USD"> 321534 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 93551 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 9 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 411701 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-04-012023-06-30" decimals="0" unitRef="USD"> 411710 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> -120000 </us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2023-04-012023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> -1200 </us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 120000 </us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 12 </us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1188 </us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:NetIncomeLoss contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -2980552 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2023-04-012023-06-30" decimals="0" unitRef="USD"> -2980552 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1398158 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2023-06-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 13982 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 3982608 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 399 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 173695154 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -161305671 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD"> 12403864 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1164135 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> 1164135 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 329571 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> 329571 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 685033 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 69 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1853921 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> 1853990 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:NetIncomeLoss contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -2925492 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> -2925492 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1398158 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2023-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 13982 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 4667641 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 468 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 177042781 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -164231163 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 12826068 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1543158 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 15432 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 3520391 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 353 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 155727292 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -134146128 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 21596949 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 97828 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 10 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1164125 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-01-012022-03-31" decimals="0" unitRef="USD"> 1164135 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 2138949 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-01-012022-03-31" decimals="0" unitRef="USD"> 2138949 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 13500 </us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 1 </us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 72818 </us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-01-012022-03-31" decimals="0" unitRef="USD"> 72819 </us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -4816150 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-03-31" decimals="0" unitRef="USD"> -4816150 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1543158 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 15432 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 3631719 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 364 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 159103184 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -138962278 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD"> 20156702 </us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 6220 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 1 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1190349 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-04-012022-06-30" decimals="0" unitRef="USD"> 1190350 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1865297 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-04-012022-06-30" decimals="0" unitRef="USD"> 1865297 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 5770 </us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 48504 </us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2022-04-012022-06-30" decimals="0" unitRef="USD"> 48504 </us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -4675241 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2022-04-012022-06-30" decimals="0" unitRef="USD"> -4675241 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1543158 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 15432 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 3643709 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 365 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 162207334 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -143637519 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD"> 18585612 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1543158 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 15432 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 3643709 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 365 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 162207334 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -143637519 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD"> 18585612 </us-gaap:StockholdersEquity>
<BRTX:StockIssuedDuringPeriodSharesExchange contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> -1543158 </BRTX:StockIssuedDuringPeriodSharesExchange>
<BRTX:StockIssuedDuringPeriodValueExchange contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesAConvertiblePreferredStockMember" decimals="0" unitRef="USD"> -15432 </BRTX:StockIssuedDuringPeriodValueExchange>
<BRTX:StockIssuedDuringPeriodSharesExchange contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1543158 </BRTX:StockIssuedDuringPeriodSharesExchange>
<BRTX:StockIssuedDuringPeriodValueExchange contextRef="From2022-07-012022-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 15432 </BRTX:StockIssuedDuringPeriodValueExchange>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 6218 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1209231 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 1209231 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 1865297 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 1865297 </us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> -3477 </us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -4655825 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> -4655825 </us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1543158 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 15432 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 3646450 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 365 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 165281862 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -148293344 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 17004315 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1543158 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_PreferredStockMember_custom_SeriesBConvertiblePreferredStockMember" decimals="0" unitRef="USD"> 15432 </us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 3646450 </us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 365 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" decimals="0" unitRef="USD"> 165281862 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" decimals="0" unitRef="USD"> -148293344 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 17004315 </us-gaap:StockholdersEquity>
<us-gaap:NetIncomeLoss contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> -11590266 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> -14147216 </us-gaap:NetIncomeLoss>
<us-gaap:DepreciationAndAmortization contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 123022 </us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 88751 </us-gaap:DepreciationAndAmortization>
<us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> -18598 </us-gaap:MarketableSecuritiesUnrealizedGainLoss>
<us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> -19895 </us-gaap:MarketableSecuritiesUnrealizedGainLoss>
<us-gaap:ShareBasedCompensation contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 6318562 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 9554582 </us-gaap:ShareBasedCompensation>
<BRTX:GainOnPppLoanForgiveness contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 250000 </BRTX:GainOnPppLoanForgiveness>
<BRTX:NoncashLeaseExpense contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 87034 </BRTX:NoncashLeaseExpense>
<BRTX:NoncashLeaseExpense contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 87033 </BRTX:NoncashLeaseExpense>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 23300 </us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 40000 </us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> -37151 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> -80135 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 56453 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 417674 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 418882 </us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> -20321 </us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> -102921 </us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
<us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> -87945 </us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> -4656785 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> -4297412 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 3690238 </us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 437842 </us-gaap:PaymentsToAcquireMarketableSecurities>
<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 9933562 </us-gaap:PaymentsToAcquireMarketableSecurities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 101019 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 222642 </us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 3151377 </us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> -10156204 </us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 411710 </us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 1853990 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 2265700 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 760292 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> -14453616 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 1676577 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD"> 21026727 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 2436869 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 6573111 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zk5baastTt03" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_82C_z9SqEJgho9vb">NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate History</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (“Stem Pearls”). BioRestorative Therapies, Inc. and its subsidiary are referred to collectively as “BRT” or the “Company”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 29, 2022, the Company reincorporated from Delaware to Nevada. The reincorporation was structured as a statutory merger of BioRestorative Therapies, Inc., a Delaware corporation, with and into its wholly-owned subsidiary, BioRestorative Therapies, Inc., a Nevada corporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and satisfying liabilities in the normal course of business. For the nine months ended September 30, 2023, the Company had a net loss of $<span id="xdx_909_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20230930_zltBJEG6cgrc" title="Net loss">11.6</span> million (of which, $<span id="xdx_905_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20230930_zA7bZsFhANU3" title="Share based compensation">6.3</span> million was attributable to non-cash stock-based compensation) and negative cash flows from operations of $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20230101__20230930_z5Pd4pMfKUh9" title="Cash flows from operations">4.7</span> million. The Company’s operating activities consume the majority of its cash resources. The Company anticipates that it will continue to incur net losses as it executes its development plans throughout 2023 and beyond, as well as other potential strategic and business development initiatives. In addition, the Company has had and expects to have negative cash flows from operations, at least into the near future. The Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand, investments in marketable securities and additional infusions of cash from equity and debt financing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 14, 2023, the Company entered into a sales agreement with JonesTrading Institutional Services LLC for an at-the-market (“ATM”) offering of the Company’s Common Stock, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230414__dei--LegalEntityAxis__custom--JonesTradingInstitutionalServicesLLCMember_ztAQjJAWCVOk" title="Common stock, par value">0.0001</span> per share, at an aggregate offering price of up to $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230413__20230414__dei--LegalEntityAxis__custom--JonesTradingInstitutionalServicesLLCMember_zMrS3tnGsGV1" title="Net proceeds">3.7</span> million. During the nine months ended September 30, 2023, net proceeds of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230930_zqdoYbzCgg8i" title="Issuance of common stock">411,710</span> were received from the issuance of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930_zoh0k60pefsc" title="Issuance of common stock, shares">93,551</span> shares of Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 13, 2023, the Company sold an aggregate of <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230712__20230713_zGGFFybHf1w3" title="Sale of aggregate shares">685,033</span> shares of Common Stock to several institutional buyers and accredited investors in a registered direct offering at an offering price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20230713_zirjvCQmHboe" title="Offering price">3.03</span> per share. The offering closed on July 13, 2023, with net proceeds of approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230712__20230713_zbN289rOfvu1" title="Net proceeds offering price">1.9</span> million. The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy candidate, <i>BRTX-100</i>, pre-clinical research and development with respect to its metabolic <i>ThermoStem Program </i>and for general corporate purposes and working capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on cash on hand as of September 30, 2023, the Company believes it has sufficient cash to fund operations for the twelve months subsequent to the filing date of this Form 10-Q.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current funds noted above will not be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the unaudited condensed   consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Business Operations</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at <span style="text-decoration: underline">www.biorestorative.com</span>. The information contained in our website is not intended to be incorporated by reference into this Quarterly Report. BRT is currently developing a Disc/Spine Program referred to as “brtxDISC”. Its lead cell therapy candidate, <i>BRTX-100</i>, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. BRT is investigating the expansion of the clinic application of <i>BRTX-100 </i>to other indications within the body. BRT is also engaging in research efforts with respect to a platform technology utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders and has labeled this initiative its ThermoStem Program. Further, BRT has a license for a patented curved needle device that is a needle system designed to deliver cells and/or other therapeutic products or material to the spine and discs or other potential sites.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">In September 2023, BRT announced that it had entered into a supply agreement with a supplier of biologic-based cosmetics pursuant to which BRT will manufacture tissue-based biologics for use in the production of cosmetic and aesthetic applications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:NetIncomeLoss contextRef="From2023-01-01to2023-09-30" decimals="-5" unitRef="USD"> -11600000 </us-gaap:NetIncomeLoss>
<us-gaap:ShareBasedCompensation contextRef="From2023-01-01to2023-09-30" decimals="-5" unitRef="USD"> 6300000 </us-gaap:ShareBasedCompensation>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2023-01-01to2023-09-30" decimals="-5" unitRef="USD"> -4700000 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2023-04-14_custom_JonesTradingInstitutionalServicesLLCMember" decimals="INF" unitRef="USDPShares"> 0.0001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2023-04-132023-04-14_custom_JonesTradingInstitutionalServicesLLCMember" decimals="-5" unitRef="USD"> 3700000 </us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 411710 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2023-01-01to2023-09-30" decimals="INF" unitRef="Shares"> 93551 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2023-07-122023-07-13" decimals="INF" unitRef="Shares"> 685033 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockPricePerShare contextRef="AsOf2023-07-13" decimals="INF" unitRef="USDPShares"> 3.03 </us-gaap:SaleOfStockPricePerShare>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2023-07-122023-07-13" decimals="-5" unitRef="USD"> 1900000 </us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_801_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zBMVWiADO78b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_82D_zC4U8hDVuYw5">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zq3O1xrezvA3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zRvbTNF76Xj3">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting policies presented below is designed to assist in understanding the Company’s unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 27, 2023 (the “Annual Report”). The summary of significant accounting policies presented below is designed to assist in understanding the Company’s unaudited condensed consolidated financial statements. Such unaudited condensed consolidated financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zKvmG4BIjtAc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zCSlKEWMJ1I9">Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--UseOfEstimates_zPBkiwxWJjac" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zYGbRTRHGtu1">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates which may cause the Company’s future results to be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zrimLmVrEhFe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zQGtVUg8LqM8">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution. The Company maintains deposits in its cash account in excess of the Federal Deposit Insurance Corporation coverage of $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zzJHfAlCBZQ8" title="FDIC insured limit">250,000</span>. As of September 30, 2023, the Company has not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The royalties related to the Company’s sublicense comprised all of the Company’s revenue during the three and nine months ended September 30, 2023 and 2022.</span></p> <p id="xdx_85D_zxnnmo2s99ac" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Summary of Significant Accounting Policies</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting Standards, in the Annual Report. During the three and nine months ended September 30, 2023, the Company did not make any changes to its significant accounting policies, except as described below with respect to recent accounting pronouncements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zI902Y2ZlA8a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zQ1TjvUhNtve">Fair Value Measurements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined in ASC 820, <i>Fair Value Measurements and Disclosures </i>(“ASC 820”), fair value is the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally-developed methodologies that result in management’s best estimate of fair value.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p> <p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zqD0tzx4Gtl7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_z1xtNwhT2Uy1" style="display: none"><span>SCHEDULE OF FAIR VALUE RECURRING BASIS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities<br/> (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%">Marketable securities as of September 30, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230930_zYMNC1W95Yf8" style="width: 11%; text-align: right" title="Cash and cash equivalents, fair value disclosure">9,801,837</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGKOavMBwC1a" style="width: 11%; text-align: right" title="Cash and cash equivalents, fair value disclosure">9,801,837</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkB61PsKHNdl" style="width: 11%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0785">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwzTZogKC2zd" style="width: 11%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Marketable securities as of December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zkN3teIU9XNj" style="text-align: right" title="Assets fair value disclosure">13,072,831</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfhlB97Y61z" style="text-align: right" title="Assets fair value disclosure">13,072,831</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYimJ0JFfsfe" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0793">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjIURSd57AO4" style="text-align: right" title="Marketable securities fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0795">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_z9jZfH2Alzs7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zHWTjTGVLnKk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zUH53J8lE7jc">Fair Value of Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of cash, accounts receivable, and accounts payable approximate their fair values based on the short-term maturity of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zYxxxELNz6rj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zIcWBjS81uz9">Net Loss per Common Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year. All outstanding options and warrants are considered potential Common Stock. The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding convertible preferred stock is considered Common Stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of Common Stock equivalents is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company’s computation of diluted net loss per common share for the three and nine months ended September 30, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zS1h45gNLZ7g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company’s net loss position even though the exercise or conversion price could be less than the average market price of the common shares:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BE_zwPSuR36xR98" style="display: none">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zRTKQousF0D5" style="width: 14%; text-align: right" title="Total">1,466,890</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_z4X108aOsezb" style="width: 14%; text-align: right" title="Total">864,609</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zd2TFJ9bVoF1" style="text-align: right" title="Total potentially dilutive shares">4,791,048</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zoQcDf6zBPF3" style="text-align: right" title="Total potentially dilutive shares">4,739,733</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unvested RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zL4OruZnMsQc" style="text-align: right" title="Unvested">97,827</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zPRvFLhgG6Gk" style="text-align: right" title="Unvested">208,086</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zXzkLxvYhiQ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zV7sW6qaupI5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0817">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930_fKDIp_zbL0yw5RCo5l" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">7,753,923</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930_fKDIp_zHFcIoZoSNM7" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">5,812,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zVChkjuAI4lj" style="width: 14%; text-align: right" title="Total">1,466,890</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zvLOmDjgcGJd" style="width: 14%; text-align: right" title="Total">864,609</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zTpfmouLGIue" style="text-align: right" title="Total potentially dilutive shares">4,791,048</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zxxxaZRAB2i7" style="text-align: right" title="Total potentially dilutive shares">4,739,733</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unvested RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_z9qwWlGVSLp1" style="text-align: right" title="Unvested">97,827</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zsanbZdSket9" style="text-align: right" title="Unvested">208,086</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zCNt7WKnpO48" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zTxBzEWL6zTj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930_fKDIp_zmA3Gx2F6bT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">7,753,923</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930_fKDIp_ziieBTgNf5Kd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">5,812,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zVKLTY8FOgv" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqfAGli1Gi82" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zz52OfzyGOA2">Recently Adopted Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses,</i> which requires entities to estimate all expected credit losses for financial assets measured at amortized cost basis, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted this guidance on January 1, 2023. The adoption of this accounting standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements.</span></p> <p id="xdx_858_zH4bJRUiKC16" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zq3O1xrezvA3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zRvbTNF76Xj3">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting policies presented below is designed to assist in understanding the Company’s unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 27, 2023 (the “Annual Report”). The summary of significant accounting policies presented below is designed to assist in understanding the Company’s unaudited condensed consolidated financial statements. Such unaudited condensed consolidated financial statements and accompanying notes are the representations of Company’s management, who is responsible for their integrity and objectivity. Operating results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_84D_eus-gaap--ConsolidationPolicyTextBlock_zKvmG4BIjtAc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zCSlKEWMJ1I9">Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-09-30">
<p id="xdx_849_eus-gaap--UseOfEstimates_zPBkiwxWJjac" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zYGbRTRHGtu1">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates which may cause the Company’s future results to be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:UseOfEstimates>
<us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-01to2023-09-30">
<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zrimLmVrEhFe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zQGtVUg8LqM8">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution. The Company maintains deposits in its cash account in excess of the Federal Deposit Insurance Corporation coverage of $<span id="xdx_908_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zzJHfAlCBZQ8" title="FDIC insured limit">250,000</span>. As of September 30, 2023, the Company has not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The royalties related to the Company’s sublicense comprised all of the Company’s revenue during the three and nine months ended September 30, 2023 and 2022.</span></p>
</us-gaap:ConcentrationRiskCreditRisk>
<us-gaap:CashFDICInsuredAmount contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 250000 </us-gaap:CashFDICInsuredAmount>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zI902Y2ZlA8a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_zQ1TjvUhNtve">Fair Value Measurements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined in ASC 820, <i>Fair Value Measurements and Disclosures </i>(“ASC 820”), fair value is the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally-developed methodologies that result in management’s best estimate of fair value.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p> <p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zqD0tzx4Gtl7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_z1xtNwhT2Uy1" style="display: none"><span>SCHEDULE OF FAIR VALUE RECURRING BASIS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities<br/> (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%">Marketable securities as of September 30, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230930_zYMNC1W95Yf8" style="width: 11%; text-align: right" title="Cash and cash equivalents, fair value disclosure">9,801,837</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGKOavMBwC1a" style="width: 11%; text-align: right" title="Cash and cash equivalents, fair value disclosure">9,801,837</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkB61PsKHNdl" style="width: 11%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0785">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwzTZogKC2zd" style="width: 11%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Marketable securities as of December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zkN3teIU9XNj" style="text-align: right" title="Assets fair value disclosure">13,072,831</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfhlB97Y61z" style="text-align: right" title="Assets fair value disclosure">13,072,831</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYimJ0JFfsfe" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0793">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjIURSd57AO4" style="text-align: right" title="Marketable securities fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0795">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_z9jZfH2Alzs7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zqD0tzx4Gtl7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B1_z1xtNwhT2Uy1" style="display: none"><span>SCHEDULE OF FAIR VALUE RECURRING BASIS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements at reporting date using:</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Quoted prices in active markets for identical liabilities<br/> (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant other observable inputs (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Significant unobservable inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%">Marketable securities as of September 30, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20230930_zYMNC1W95Yf8" style="width: 11%; text-align: right" title="Cash and cash equivalents, fair value disclosure">9,801,837</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zGKOavMBwC1a" style="width: 11%; text-align: right" title="Cash and cash equivalents, fair value disclosure">9,801,837</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zkB61PsKHNdl" style="width: 11%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0785">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20230930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwzTZogKC2zd" style="width: 11%; text-align: right" title="Cash and cash equivalents, fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Marketable securities as of December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231_zkN3teIU9XNj" style="text-align: right" title="Assets fair value disclosure">13,072,831</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zfhlB97Y61z" style="text-align: right" title="Assets fair value disclosure">13,072,831</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYimJ0JFfsfe" style="text-align: right" title="Assets fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0793">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjIURSd57AO4" style="text-align: right" title="Marketable securities fair value disclosure"><span style="-sec-ix-hidden: xdx2ixbrl0795">-</span></td><td style="text-align: left"> </td></tr> </table>
</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
<us-gaap:AssetsFairValueDisclosure contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 9801837 </us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="AsOf2023-09-30_us-gaap_FairValueInputsLevel1Member" decimals="0" unitRef="USD"> 9801837 </us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 13072831 </us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" decimals="0" unitRef="USD"> 13072831 </us-gaap:AssetsFairValueDisclosure>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-09-30">
<p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zHWTjTGVLnKk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zUH53J8lE7jc">Fair Value of Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of cash, accounts receivable, and accounts payable approximate their fair values based on the short-term maturity of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zYxxxELNz6rj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zIcWBjS81uz9">Net Loss per Common Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year. All outstanding options and warrants are considered potential Common Stock. The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding convertible preferred stock is considered Common Stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of Common Stock equivalents is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company’s computation of diluted net loss per common share for the three and nine months ended September 30, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zS1h45gNLZ7g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company’s net loss position even though the exercise or conversion price could be less than the average market price of the common shares:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BE_zwPSuR36xR98" style="display: none">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zRTKQousF0D5" style="width: 14%; text-align: right" title="Total">1,466,890</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_z4X108aOsezb" style="width: 14%; text-align: right" title="Total">864,609</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zd2TFJ9bVoF1" style="text-align: right" title="Total potentially dilutive shares">4,791,048</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zoQcDf6zBPF3" style="text-align: right" title="Total potentially dilutive shares">4,739,733</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unvested RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zL4OruZnMsQc" style="text-align: right" title="Unvested">97,827</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zPRvFLhgG6Gk" style="text-align: right" title="Unvested">208,086</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zXzkLxvYhiQ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zV7sW6qaupI5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0817">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930_fKDIp_zbL0yw5RCo5l" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">7,753,923</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930_fKDIp_zHFcIoZoSNM7" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">5,812,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zVChkjuAI4lj" style="width: 14%; text-align: right" title="Total">1,466,890</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zvLOmDjgcGJd" style="width: 14%; text-align: right" title="Total">864,609</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zTpfmouLGIue" style="text-align: right" title="Total potentially dilutive shares">4,791,048</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zxxxaZRAB2i7" style="text-align: right" title="Total potentially dilutive shares">4,739,733</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unvested RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_z9qwWlGVSLp1" style="text-align: right" title="Unvested">97,827</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zsanbZdSket9" style="text-align: right" title="Unvested">208,086</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zCNt7WKnpO48" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zTxBzEWL6zTj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930_fKDIp_zmA3Gx2F6bT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">7,753,923</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930_fKDIp_ziieBTgNf5Kd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">5,812,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zVKLTY8FOgv" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_891_eus-gaap--ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_zS1h45gNLZ7g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables summarize the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company’s net loss position even though the exercise or conversion price could be less than the average market price of the common shares:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BE_zwPSuR36xR98" style="display: none">SCHEDULE OF WEIGHTED AVERAGE DILUTIVE COMMON SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zRTKQousF0D5" style="width: 14%; text-align: right" title="Total">1,466,890</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_z4X108aOsezb" style="width: 14%; text-align: right" title="Total">864,609</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zd2TFJ9bVoF1" style="text-align: right" title="Total potentially dilutive shares">4,791,048</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zoQcDf6zBPF3" style="text-align: right" title="Total potentially dilutive shares">4,739,733</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unvested RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zL4OruZnMsQc" style="text-align: right" title="Unvested">97,827</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zPRvFLhgG6Gk" style="text-align: right" title="Unvested">208,086</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zXzkLxvYhiQ9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zV7sW6qaupI5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0817">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230701__20230930_fKDIp_zbL0yw5RCo5l" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">7,753,923</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930_fKDIp_zHFcIoZoSNM7" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">5,812,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zVChkjuAI4lj" style="width: 14%; text-align: right" title="Total">1,466,890</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_fKDIp_zvLOmDjgcGJd" style="width: 14%; text-align: right" title="Total">864,609</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zTpfmouLGIue" style="text-align: right" title="Total potentially dilutive shares">4,791,048</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_fKDIp_zxxxaZRAB2i7" style="text-align: right" title="Total potentially dilutive shares">4,739,733</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unvested RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_z9qwWlGVSLp1" style="text-align: right" title="Unvested">97,827</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDIp_zsanbZdSket9" style="text-align: right" title="Unvested">208,086</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zCNt7WKnpO48" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes">1,398,158</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zTxBzEWL6zTj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Convertible notes"><span style="-sec-ix-hidden: xdx2ixbrl0837">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930_fKDIp_zmA3Gx2F6bT6" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">7,753,923</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930_fKDIp_ziieBTgNf5Kd" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive securities">5,812,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 1466890 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-07-012022-09-30_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 864609 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2023-07-012023-09-30_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 4791048 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-07-012022-09-30_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 4739733 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2023-07-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" unitRef="Shares"> 97827 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-07-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" unitRef="Shares"> 208086 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2023-07-012023-09-30_us-gaap_ConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1398158 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2023-07-012023-09-30" decimals="INF" unitRef="Shares"> 7753923 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-07-012022-09-30" decimals="INF" unitRef="Shares"> 5812428 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2023-01-012023-09-30_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 1466890 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember" decimals="INF" unitRef="Shares"> 864609 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 4791048 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 4739733 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" unitRef="Shares"> 97827 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" unitRef="Shares"> 208086 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2023-01-012023-09-30_us-gaap_ConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1398158 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2023-01-01to2023-09-30" decimals="INF" unitRef="Shares"> 7753923 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2022-01-012022-09-30" decimals="INF" unitRef="Shares"> 5812428 </us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqfAGli1Gi82" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zz52OfzyGOA2">Recently Adopted Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments - Credit Losses,</i> which requires entities to estimate all expected credit losses for financial assets measured at amortized cost basis, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted this guidance on January 1, 2023. The adoption of this accounting standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements.</span></p>
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_zDusdmkzcKcg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 - <span style="text-transform: uppercase"><span id="xdx_826_z5X4ueFM3yz9">INTANGIBLE ASSETS</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a party to a license agreement with a stem cell treatment company (the “SCTC”) (as amended) (the “SCTC Agreement”). Pursuant to the SCTC Agreement, the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from the SCTC to utilize or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or spine (and other parts of the body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or sublicense a certain method for culturing cells. Pursuant to the license agreement with the SCTC, certain performance milestones (or payouts in lieu of performance milestones) had to be satisfied in order for the Company to maintain its exclusive rights with regard to the disc/spine technology. The Company did not timely satisfy the third of these performance milestones (which needed to be satisfied by February 2022). Accordingly, such rights became non-exclusive. However, in November 2022, the Company entered into an amended agreement under which it paid $<span id="xdx_90F_eus-gaap--PaymentsToAcquireIntangibleAssets_c20221101__20221130_zusGK4XHHF16" title="Payment to acquire intangible assets">175,000</span> and issued <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTuWq8WVGH49" title="Warrants issued">51,370</span> warrants, with a fair value of $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20221101__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYVghQ7czDwe" title="Fair value of warrants">117,030</span>, in exchange for renewed exclusivity. The consideration transferred to the SCTC in exchange for exclusivity was capitalized to intangible assets on the Company’s consolidated balance sheet as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2017, the Company received authorization from the Food and Drug Administration (the “FDA”) to proceed with a Phase 2 clinical trial. In March 2022, the United States Patent and Trademark Office issued a patent relating to the Company’s BRTX-100 clinical program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zPdL78ubvNaf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zKJvg9WZzPGe" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance as of January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zXauk9rsRm6f" style="width: 11%; text-align: right" title="Finite Lived Intangible Assets, Gross, Beginning balance">3,676</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zcEQyj3zkFla" style="width: 11%; text-align: right" title="Finite Lived Intangible Assets, Gross, Beginning balance">1,593,530</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_di_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zKr0Qio2ObXe" style="width: 11%; text-align: right" title="Finite Lived Intangible Assets, Accumulated Amortization, Beginning Balance">(793,768</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20230101__20230930_z9e2lT1ErSv5" style="width: 11%; text-align: right" title="Finite Lived Intangible Assets, Net, Beginning Balance">803,438</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_z0z3u9wS8yVg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization Expense"><span style="-sec-ix-hidden: xdx2ixbrl0863">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zsxRaUDa0XS2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization Expense"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zJ2pmjlNLcaf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization Expense">(67,310</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20230930_z2Ttq2SRV2C" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization Expense">(67,310</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zhaa88rmCJo9" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zwng0hCUTxSd" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance">1,593,530</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zU54sU4hK71j" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance">(861,078</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pp0p0_c20230101__20230930_zTS3FU3zV0D6" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, Ending Balance">736,128</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Weighted average remaining amortization period as of September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zNeGDPBzSj33" title="Finite Lived Intangible Assets, weighted average amortization period"><span style="-sec-ix-hidden: xdx2ixbrl0879">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_ztZ0wf8HP4Ji" title="Finite Lived Intangible Assets, weighted average amortization period">10.58</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zbGXhy4veTC9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_znnaowo8Z9yc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated amortization of intangible assets consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zTk7V9pNtNi8" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance as of January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zjMEyTeNDEA8" style="width: 14%; text-align: right" title="Beginning Balance">3,676</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDoyB7GrYGtj" style="width: 14%; text-align: right" title="Beginning Balance">790,092</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zuw4OwT2cYn9" style="width: 14%; text-align: right" title="Beginning Balance">793,768</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zDPt2AZHRfM2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDvbI2ECUEna" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense">67,310</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_ztdmE8YD2iwi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense">67,310</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of September 30, 2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zFTaExr7ackg" style="text-align: right" title="Beginning Balance">3,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zSjzvOGbqPQ2" style="text-align: right" title="Beginning Balance">857,402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zixc1Csxulk8" style="text-align: right" title="Ending Balance">861,078</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AA_zLgPO7ZqBbl5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:IntangibleAssetsDisclosureTextBlock>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2022-11-012022-11-30" decimals="0" unitRef="USD"> 175000 </us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2022-11-30_us-gaap_WarrantMember" decimals="INF" unitRef="Shares"> 51370 </us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="From2022-11-012022-11-30_us-gaap_WarrantMember" decimals="0" unitRef="USD"> 117030 </us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_897_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zPdL78ubvNaf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_zKJvg9WZzPGe" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Balance as of January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zXauk9rsRm6f" style="width: 11%; text-align: right" title="Finite Lived Intangible Assets, Gross, Beginning balance">3,676</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iS_pp0p0_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zcEQyj3zkFla" style="width: 11%; text-align: right" title="Finite Lived Intangible Assets, Gross, Beginning balance">1,593,530</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNS_di_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zKr0Qio2ObXe" style="width: 11%; text-align: right" title="Finite Lived Intangible Assets, Accumulated Amortization, Beginning Balance">(793,768</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iS_pp0p0_c20230101__20230930_z9e2lT1ErSv5" style="width: 11%; text-align: right" title="Finite Lived Intangible Assets, Net, Beginning Balance">803,438</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_z0z3u9wS8yVg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization Expense"><span style="-sec-ix-hidden: xdx2ixbrl0863">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zsxRaUDa0XS2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization Expense"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_iN_pp0p0_di_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zJ2pmjlNLcaf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization Expense">(67,310</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_iN_di_c20230101__20230930_z2Ttq2SRV2C" style="border-bottom: Black 1.5pt solid; text-align: right" title="Finite Lived Intangible Assets, Amortization Expense">(67,310</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zhaa88rmCJo9" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance">3,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iE_pp0p0_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zwng0hCUTxSd" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Gross, Ending balance">1,593,530</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNE_pp0p0_di_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zU54sU4hK71j" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Accumulated Amortization, Ending Balance">(861,078</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsNet_iE_pp0p0_c20230101__20230930_zTS3FU3zV0D6" style="border-bottom: Black 2.5pt double; text-align: right" title="Finite Lived Intangible Assets, Net, Ending Balance">736,128</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Weighted average remaining amortization period as of September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_c20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zNeGDPBzSj33" title="Finite Lived Intangible Assets, weighted average amortization period"><span style="-sec-ix-hidden: xdx2ixbrl0879">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_ztZ0wf8HP4Ji" title="Finite Lived Intangible Assets, weighted average amortization period">10.58</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2022-12-31_custom_PatentsAndTrademarksMember" decimals="0" unitRef="USD"> 3676 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2022-12-31_custom_LicensesMember" decimals="0" unitRef="USD"> 1593530 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember" decimals="0" unitRef="USD"> 793768 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 803438 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:AmortizationOfIntangibleAssets contextRef="From2023-01-012023-09-30_custom_AccumulatedAmortizationMember" decimals="0" unitRef="USD"> 67310 </us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 67310 </us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2023-09-30_custom_PatentsAndTrademarksMember" decimals="0" unitRef="USD"> 3676 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2023-09-30_custom_LicensesMember" decimals="0" unitRef="USD"> 1593530 </us-gaap:FiniteLivedIntangibleAssetsGross>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2023-09-30_custom_AccumulatedAmortizationMember" decimals="0" unitRef="USD"> 861078 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 736128 </us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="AsOf2023-09-30_custom_LicensesMember"> P10Y6M29D </us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_893_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_znnaowo8Z9yc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated amortization of intangible assets consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BF_zTk7V9pNtNi8" style="display: none">SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patents and Trademarks</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Licenses</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Balance as of January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zjMEyTeNDEA8" style="width: 14%; text-align: right" title="Beginning Balance">3,676</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDoyB7GrYGtj" style="width: 14%; text-align: right" title="Beginning Balance">790,092</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iS_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zuw4OwT2cYn9" style="width: 14%; text-align: right" title="Beginning Balance">793,768</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Amortization expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zDPt2AZHRfM2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zDvbI2ECUEna" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense">67,310</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_ztdmE8YD2iwi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization expense">67,310</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance as of September 30, 2023</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarkMember_zFTaExr7ackg" style="text-align: right" title="Beginning Balance">3,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zSjzvOGbqPQ2" style="text-align: right" title="Beginning Balance">857,402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iE_c20230101__20230930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AccumulatedAmortizationMember_zixc1Csxulk8" style="text-align: right" title="Ending Balance">861,078</td><td style="text-align: left"> </td></tr> </table>
</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31_custom_PatentsAndTrademarkMember" decimals="0" unitRef="USD"> 3676 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31_us-gaap_LicenseMember" decimals="0" unitRef="USD"> 790092 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-12-31_custom_AccumulatedAmortizationMember" decimals="0" unitRef="USD"> 793768 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:AmortizationOfIntangibleAssets contextRef="From2023-01-012023-09-30_us-gaap_LicenseMember" decimals="0" unitRef="USD"> 67310 </us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="From2023-01-012023-09-30_custom_AccumulatedAmortizationMember" decimals="0" unitRef="USD"> 67310 </us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2023-09-30_custom_PatentsAndTrademarkMember" decimals="0" unitRef="USD"> 3676 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2023-09-30_us-gaap_LicenseMember" decimals="0" unitRef="USD"> 857402 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2023-09-30_custom_AccumulatedAmortizationMember" decimals="0" unitRef="USD"> 861078 </us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_808_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_ztilmjCy6yO5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 - <span id="xdx_82B_zzUB36TZs6I3">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zzYw6YxKXlF5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other current liabilities consist of:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zMEnQ2ulOzza" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230930_zYHXQMgDb5Na" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20221231_znP8def6Socc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zJ0LFNVOGmNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accrued payroll</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">487,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">26,250</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zxUh5j68IlSj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,454</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,822</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zMlEtvcf1lt2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accrued expenses</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">548,954</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">130,072</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zuZfpnZIR4Wc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_899_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zzYw6YxKXlF5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses and other current liabilities consist of:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B3_zMEnQ2ulOzza" style="display: none">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230930_zYHXQMgDb5Na" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20221231_znP8def6Socc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_maALAOLzJ5Y_zJ0LFNVOGmNe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accrued payroll</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">487,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">26,250</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AccruedGeneralAndAdministrativeExpenses_iI_maALAOLzJ5Y_zxUh5j68IlSj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued general and administrative expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">61,454</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">103,822</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzJ5Y_zMlEtvcf1lt2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total accrued expenses</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">548,954</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">130,072</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 487500 </us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 26250 </us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
<BRTX:AccruedGeneralAndAdministrativeExpenses contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 61454 </BRTX:AccruedGeneralAndAdministrativeExpenses>
<BRTX:AccruedGeneralAndAdministrativeExpenses contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 103822 </BRTX:AccruedGeneralAndAdministrativeExpenses>
<us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 548954 </us-gaap:AccruedLiabilitiesAndOtherLiabilities>
<us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD"> 130072 </us-gaap:AccruedLiabilitiesAndOtherLiabilities>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_806_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zGZK1UvQqrhe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>NOTE 5 - <span id="xdx_826_zm6prmRx5uT9">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series A Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 8, 2021, in connection with the Company’s public offering, the Company’s Board of Directors adopted a resolution allowing for the designation and issuance of <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zctLYQAtqHk9" title="Preferred stock, shares issued">1,543,158</span> shares of the Company’s Preferred Stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0pqywySaeO5" title="Preferred stock, par value">.01</span> par value per share, designated as Series A Preferred Stock (“Series A”). The Series A had a liquidation preference of $<span id="xdx_90F_eus-gaap--PreferredStockLiquidationPreference_iI_pid_c20211108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpL4NysQwud5" title="Preferred stock, liquidation preference">0.001</span> per share. On September 8, 2022, the Company issued <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zakGJl0F7OD2" title="Preferred stock, shares issued">1,543,158</span> shares of Series B Preferred Stock (“Series B”) to Auctus Fund, LLC (“Auctus”) in exchange for an equal number of shares of the Company’s outstanding Series A. Simultaneously, the stock certificate representing the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company’s Board of Directors cancelled the Series A.  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series B Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective September 8, 2022, the Company issued <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zbwFTT1Fna8a" title="Preferred stock, shares issued">1,543,158</span> shares of Series B to Auctus in exchange for an equal number of shares of the Company’s outstanding Series A. The terms of the Series B are substantially identical to those of the Series A, except that, among other things, the limitation on beneficial ownership of Common Stock of the Company upon a conversion of the Series B into Common Stock, and the limitation on the number of votes attributable to the Series B, is <span id="xdx_90D_eus-gaap--PreferredStockVotingRights_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z2Aqidev9UE7" title="Preferred stock voting rights">9.99</span>% of the then outstanding Common Stock of the Company instead of <span id="xdx_90C_eus-gaap--PreferredStockVotingRights_pid_c20220908__20220908__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5PvXX6In231" title="Preferred stock voting rights">4.99</span>% as provided for the Series A. The Company shall, at all times, reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to redemption by the Company or any Series B holder.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dividends</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voting Rights</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law. The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled to vote more than <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBWBByYVbzc6" title="Preferred stock voting percentage">9.99</span>% of the then outstanding shares of Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conversion</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Optional Conversion - <span id="xdx_900_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zM3hL8P6n2f6" title="Preferred stock conversion term">Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into one share of Common Stock;</span> provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B to the extent that such conversion would result in beneficial ownership by such Series B holder of more than <span id="xdx_90E_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zmtfSVaovQTi" title="Preferred stock voting percentage">9.99</span>% of the outstanding shares of Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Automatic Conversion – From time to time, if an event occurs, including adjustment due to merger, consolidation, etc., subdivision or combination of Common Stock, adjustment due to distribution, purchase rights, and notice of adjustments, which has the effect of reducing a Series B holder’s beneficial ownership of shares of Common Stock to less than <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zDcdGaPuvIz8" title="Ownership percentage">9.5</span>% of the then publicly disclosed outstanding shares of Common Stock, then, within five (5) business days, the Series B holder shall provide notice to the Company to such effect, which notice shall state the number of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable detail with regard thereto, including the number of derivative securities compromising a portion of such beneficial share amount. Such notice shall have the effect of a notice of conversion with respect to the conversion of such number of shares of Series B as would increase the Series B holder’s beneficial ownership of Common Stock to <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20230101__20230930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BeneficialOwnershipMember_zmb7sYHe5Ad5" title="Preferred stock voting percentage">9.99</span>% of the then publicly disclosed outstanding shares of Common Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 4, 2023, Auctus converted <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z8QJRAoA2fx1" title="Number of shares converted">120,000</span> shares of Series B into <span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_c20230403__20230404__dei--LegalEntityAxis__custom--AuctusFundLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zFirKbawZKy6" title="Number of shares issued in conversion">120,000</span> shares of Common Stock. As of September 30, 2023, the number of shares of Series B remaining outstanding after giving effect to such conversion was <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20230930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zkecYLf4IBvh" title="Preferred stock, shares outstanding">1,398,158</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Common Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On July 13, 2023, the Company sold an aggregate of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230712__20230713_zAVQKDw548s8" title="Sale of aggregate shares">685,033</span> shares of Common Stock to several institutional buyers and accredited investors in a registered direct offering at an offering price of $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20230713_zHTDKZMnZfd5" title="Offering price">3.03</span> per share. The offering closed on July 13, 2023, with net proceeds of approximately $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20230712__20230713_zax4NNi3jtA6" title="Net proceeds offering price">1.9</span> million. The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy candidate, <i>BRTX-100</i>, pre-clinical research and development with respect to its metabolic <i>ThermoStem Program </i>and for general corporate purposes and working capital. As of September 30, 2023, there were <span id="xdx_906_eus-gaap--CommonStockSharesOutstanding_iI_c20230930_zrh75cXDV2T2" title="Common stock, shares outstanding">4,667,641</span> shares of Common Stock outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021 Stock Incentive Plan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 18, 2021, the Company’s Board of Directors adopted the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan (the “2021 Plan”). The 2021 Plan was approved by the Company’s stockholders on August 17, 2021. Pursuant to the 2021 Plan, a total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210318__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember_zIcPQlvLh1Jg">1,175,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock were initially authorized to be issued pursuant to the grant of stock options, restricted stock units, restricted stock, stock appreciation rights and other incentive awards. On December 10, 2021, the Company’s Board of Directors approved an amendment to increase the number of shares of Common Stock authorized to be issued from <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zgvDqg6xaxA1">1,175,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20211210__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zkMX2VkLFmt9">2,500,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Such amendment was approved by the Company’s stockholders on November 3, 2022. On July 13, 2023, the Company’s Board of Directors approved an amendment <span style="background-color: white">to the 2021 Plan to increase the number of shares of common stock authorized to be issued from <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zGQr8A4RN8L">2,500,000 </span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230713__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOneStockIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zmL3wYRPV1j">3,850,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">. </span>Such amendment was approved by the Company’s stockholders on September 13, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant and Option Valuation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20230701__20230930_z5kaVG6Co2g4" title="Number of stock option issued granted of common stock">no</span> stock options granted during the three months ended September 30, 2023. The Company granted options for the purchase of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20230101__20230930_z5Vwgtw6oOUa" title="Number of option issued to purchase shares of common stock">629,017</span> shares of Common Stock during the nine months ended September 30, 2023. The grant date fair value of options issued during the nine months ended September 30, 2023 was $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20230930_zhioFi7Ciezk" title="Number of fair value of options issued">1,745,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_do_c20220701__20220930_z0ynEEfehUci" title="Number of stock option issued granted of common stock">no</span> stock options granted during the three months ended September 30, 2022. The Company granted options for the purchase of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_c20220101__20220930_z7yA3F2kiuL4" title="Number of option issued to purchase shares of common stock">25,000</span> shares of Common Stock during the nine months ended September 30, 2022. The grant date fair value of options issued during the nine months ended September 30, 2022 was $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220930_zdje7ghq1Xc5" title="Number of fair value of options issued">122,117</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z5KCcaDk3Hj5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In applying the Black-Scholes option pricing model to stock options granted during the nine months ended September 30, 2023 and 2022, the Company used the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zhktZP9gZx2a">SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS</span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the <br/> Nine Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the <br/> Nine Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Risk free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQthonApWyA3" title="Risk free interest rate">4.22</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbCeQT8vfT26" title="Risk free interest rate">2.42</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbXhN9uMuBNi" title="Expected term (years)">3.50</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zH9KlcbKnEEc" title="Expected term (years)">3.50</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zICNwJWPRYYj" title="Expected volatility">175</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSNhrbCU5QWa" title="Expected volatility">286</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYOhHgvLGJUg" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5u50zAaldK7" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A7_ziWS7oGHhZ2c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsd7Ha6E5t1e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the stock option activity during the nine months ended September 30, 2023 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zusS16vRMPEj">SCHEDULE OF STOCK OPTION ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding, January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zQeocvrZWa6" style="width: 14%; text-align: right" title="Number of Options, Outstanding, Beginning balance">864,639</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930_z0bmlorAEhFf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance">5.08</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_zzQEn72vZ1X1" style="text-align: right" title="Number of Options, Granted">629,017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930_z2bI2VchR7Mf" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.91</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230930_zplXtLmrkz38" style="text-align: right" title="Number of Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zSaeZaRBRFSl" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230930_zrOwS7fDw8bf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(26,766</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230930_zp5EXgaSKetb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">5.08</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, September 30, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zi1DVttNFoAk" style="text-align: right" title="Number of Options, Outstanding, Ending balance">1,466,890</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930_zbRpWNpl2CX8" style="text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending balance">4.17</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, September 30, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zaO1LA0kuKo5" style="text-align: right" title="Number of Options, Exercisable, Ending balance">1,122,671</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20230930_zXh80ceORivi" style="text-align: right" title="Weighted Average Exercise Price, Exercisable, Ending balance">4.69</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A9_zxB87Fnon3k3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted Stock Units</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Company’s 2021 Stock Incentive Plan, the Company may grant restricted stock units (“RSUs”) to employees, consultants or non-employee directors (“Eligible Individuals”). The number, terms and conditions of the RSUs that are granted to Eligible Individuals are determined on an individual basis by the 2021 Plan administrator. On the distribution date, the Company shall issue to the Eligible Individual one unrestricted, fully transferable share of the Company’s Common Stock (or the fair market value of one such share in cash) for each vested and nonforfeitable RSU.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z9jxEMMuoyJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s unvested RSUs as of September 30, 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_ziyAmPTga3Rd">SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Outstanding, December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaawFAgGz4l4" style="width: 18%; text-align: right" title="Number of shares outstanding beginning">201,870</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOamO4FcaObg" style="text-align: right" title="Number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zljnIDesuCRd" style="text-align: right" title="Number of shares forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1023">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkNCA4NNLHF8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares vested">(104,043</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGfoRH7g1Pi2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending">97,827</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zYFYSMDJy2Le" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z4lbOYssf2l1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents stock compensation by award type:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zrYRAthISTg3">SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zof8PpfunRid" style="width: 14%; text-align: right" title="Stock-based compensation award">329,571</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgLn7JvAXXe6" style="width: 14%; text-align: right" title="Stock-based compensation award">1,865,297</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvzM4gg9Dw49" style="text-align: right" title="Stock-based compensation award">1,164,135</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zECbOiiJgRLk" style="text-align: right" title="Stock-based compensation award">1,190,349</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Shares issued for services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20230930__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zAXfAqcA3Ahl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20220930__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zq94rktQ1iw8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award">18,923</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20230930_zU2qaRJ0VqX1" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award">1,493,706</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20220930_z9W4qJV0x3p2" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award">3,074,528</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Nine Months Ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0vCeJeR8sMd" style="width: 14%; text-align: right" title="Stock-based compensation award">2,841,533</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB9YizVXdPy2" style="width: 14%; text-align: right" title="Stock-based compensation award">5,869,543</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzzBwVyqYow8" style="text-align: right" title="Stock-based compensation award">3,477,020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOR4pvSqWrH9" style="text-align: right" title="Stock-based compensation award">3,544,782</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Shares issued for services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zg72oyX9peS9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zv1YtgogewH5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award">140,245</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230930_zZPPPzy7OAi6" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award">6,318,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930_zVYjj7m7O1Tf" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award">9,554,570</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zVoF48oGP4ki" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock based compensation is included in General and administrative expenses on the unaudited condensed consolidated statements of operations. As of September 30, 2023, unrecognized stock based compensation expense is $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20230930_zlXkgTrzKna">872,304 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a weighted average remaining amortization period of <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20230930_zeIoLiBVzQ87">0.87 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="Shares"> 1543158 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="USDPShares"> 0.01 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockLiquidationPreference contextRef="AsOf2021-11-08_us-gaap_SeriesAPreferredStockMember" decimals="INF" unitRef="USDPShares"> 0.001 </us-gaap:PreferredStockLiquidationPreference>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Shares"> 1543158 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-09-08_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Shares"> 1543158 </us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockVotingRights contextRef="From2022-09-082022-09-08_us-gaap_SeriesBPreferredStockMember"> 9.99 </us-gaap:PreferredStockVotingRights>
<us-gaap:PreferredStockVotingRights contextRef="From2022-09-082022-09-08_us-gaap_SeriesAPreferredStockMember"> 4.99 </us-gaap:PreferredStockVotingRights>
<us-gaap:PreferredStockDividendRatePercentage contextRef="From2023-01-012023-09-30_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Pure"> 0.0999 </us-gaap:PreferredStockDividendRatePercentage>
<us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="From2023-01-012023-09-30_us-gaap_SeriesBPreferredStockMember"> Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into one share of Common Stock; </us-gaap:ConvertiblePreferredStockTermsOfConversion>
<us-gaap:PreferredStockDividendRatePercentage contextRef="From2023-01-012023-09-30_us-gaap_SeriesBPreferredStockMember" decimals="INF" unitRef="Pure"> 0.0999 </us-gaap:PreferredStockDividendRatePercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2023-09-30_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember" decimals="INF" unitRef="Pure"> 0.095 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:PreferredStockDividendRatePercentage contextRef="From2023-01-012023-09-30_us-gaap_SeriesBPreferredStockMember_custom_BeneficialOwnershipMember" decimals="INF" unitRef="Pure"> 0.0999 </us-gaap:PreferredStockDividendRatePercentage>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="From2023-04-032023-04-04_custom_AuctusFundLLCMember_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 120000 </us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="From2023-04-032023-04-04_custom_AuctusFundLLCMember_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 120000 </us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2023-09-30_custom_SeriesBConvertiblePreferredStockMember" decimals="INF" unitRef="Shares"> 1398158 </us-gaap:PreferredStockSharesOutstanding>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2023-07-122023-07-13" decimals="INF" unitRef="Shares"> 685033 </us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockPricePerShare contextRef="AsOf2023-07-13" decimals="INF" unitRef="USDPShares"> 3.03 </us-gaap:SaleOfStockPricePerShare>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2023-07-122023-07-13" decimals="-5" unitRef="USD"> 1900000 </us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares"> 4667641 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2021-03-18_custom_TwoThousandTwentyOneStockIncentivePlanMember" decimals="INF" unitRef="Shares"> 1175000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember" decimals="INF" unitRef="Shares"> 1175000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-10_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember" decimals="INF" unitRef="Shares"> 2500000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MinimumMember" decimals="INF" unitRef="Shares"> 2500000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-07-13_custom_TwoThousandTwentyOneStockIncentivePlanMember_srt_MaximumMember" decimals="INF" unitRef="Shares"> 3850000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2023-07-012023-09-30" decimals="INF" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="From2023-01-01to2023-09-30" decimals="INF" unitRef="Shares"> 629017 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares"> 1745000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2022-07-012022-09-30" decimals="INF" unitRef="Shares"> 0 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="From2022-01-012022-09-30" decimals="INF" unitRef="Shares"> 25000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares"> 122117 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_899_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z5KCcaDk3Hj5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In applying the Black-Scholes option pricing model to stock options granted during the nine months ended September 30, 2023 and 2022, the Company used the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zhktZP9gZx2a">SCHEDULE OF STOCK OPTION GRANTED ASSUMPTIONS</span> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the <br/> Nine Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">For the <br/> Nine Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Risk free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zQthonApWyA3" title="Risk free interest rate">4.22</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbCeQT8vfT26" title="Risk free interest rate">2.42</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zbXhN9uMuBNi" title="Expected term (years)">3.50</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zH9KlcbKnEEc" title="Expected term (years)">3.50</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zICNwJWPRYYj" title="Expected volatility">175</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zSNhrbCU5QWa" title="Expected volatility">286</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zYOhHgvLGJUg" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z5u50zAaldK7" style="text-align: right" title="Expected dividends">0.00</td><td style="text-align: left">%</td></tr> </table>
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2023-01-012023-09-30_us-gaap_StockOptionMember" decimals="INF" unitRef="Pure"> 0.0422 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2022-01-012022-09-30_us-gaap_StockOptionMember" decimals="INF" unitRef="Pure"> 0.0242 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-09-30_us-gaap_StockOptionMember"> P3Y6M </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-09-30_us-gaap_StockOptionMember"> P3Y6M </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2023-01-012023-09-30_us-gaap_StockOptionMember" decimals="INF" unitRef="Pure"> 1.75 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2022-01-012022-09-30_us-gaap_StockOptionMember" decimals="INF" unitRef="Pure"> 2.86 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2023-01-012023-09-30_us-gaap_StockOptionMember" decimals="INF" unitRef="Pure"> 0.0000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2022-01-012022-09-30_us-gaap_StockOptionMember" decimals="INF" unitRef="Pure"> 0.0000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsd7Ha6E5t1e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the stock option activity during the nine months ended September 30, 2023 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zusS16vRMPEj">SCHEDULE OF STOCK OPTION ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding, January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zQeocvrZWa6" style="width: 14%; text-align: right" title="Number of Options, Outstanding, Beginning balance">864,639</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930_z0bmlorAEhFf" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance">5.08</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_zzQEn72vZ1X1" style="text-align: right" title="Number of Options, Granted">629,017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930_z2bI2VchR7Mf" style="text-align: right" title="Weighted Average Exercise Price, Granted">2.91</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20230101__20230930_zplXtLmrkz38" style="text-align: right" title="Number of Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zSaeZaRBRFSl" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230930_zrOwS7fDw8bf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Forfeited">(26,766</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230930_zp5EXgaSKetb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">5.08</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding, September 30, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zi1DVttNFoAk" style="text-align: right" title="Number of Options, Outstanding, Ending balance">1,466,890</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930_zbRpWNpl2CX8" style="text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending balance">4.17</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, September 30, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zaO1LA0kuKo5" style="text-align: right" title="Number of Options, Exercisable, Ending balance">1,122,671</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20230101__20230930_zXh80ceORivi" style="text-align: right" title="Weighted Average Exercise Price, Exercisable, Ending balance">4.69</td><td style="text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares"> 864639 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2022-12-31" decimals="INF" unitRef="USDPShares"> 5.08 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2023-01-01to2023-09-30" decimals="INF" unitRef="Shares"> 629017 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2023-01-01to2023-09-30" decimals="INF" unitRef="USDPShares"> 2.91 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2023-01-01to2023-09-30" decimals="INF" unitRef="Shares"> 26766 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2023-01-01to2023-09-30" decimals="INF" unitRef="USDPShares"> 5.08 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares"> 1466890 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2023-09-30" decimals="INF" unitRef="USDPShares"> 4.17 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares"> 1122671 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2023-09-30" decimals="INF" unitRef="USDPShares"> 4.69 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_89A_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_z9jxEMMuoyJ1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s unvested RSUs as of September 30, 2023 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_ziyAmPTga3Rd">SCHEDULE OF UNVESTED RESTRICTED STOCK UNITS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Outstanding, December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaawFAgGz4l4" style="width: 18%; text-align: right" title="Number of shares outstanding beginning">201,870</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOamO4FcaObg" style="text-align: right" title="Number of shares granted"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zljnIDesuCRd" style="text-align: right" title="Number of shares forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1023">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkNCA4NNLHF8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares vested">(104,043</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, September 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGfoRH7g1Pi2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares outstanding ending">97,827</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" unitRef="Shares"> 201870 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember37226718" decimals="INF" unitRef="Shares"> 104043 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2023-09-30_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" unitRef="Shares"> 97827 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_z4lbOYssf2l1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents stock compensation by award type:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zrYRAthISTg3">SCHEDULE OF STOCK COMPENSATION BY AWARD TYPE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zof8PpfunRid" style="width: 14%; text-align: right" title="Stock-based compensation award">329,571</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgLn7JvAXXe6" style="width: 14%; text-align: right" title="Stock-based compensation award">1,865,297</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvzM4gg9Dw49" style="text-align: right" title="Stock-based compensation award">1,164,135</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zECbOiiJgRLk" style="text-align: right" title="Stock-based compensation award">1,190,349</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Shares issued for services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20230930__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zAXfAqcA3Ahl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20220930__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zq94rktQ1iw8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award">18,923</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230701__20230930_zU2qaRJ0VqX1" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award">1,493,706</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20220930_z9W4qJV0x3p2" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award">3,074,528</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Nine Months Ended <br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0vCeJeR8sMd" style="width: 14%; text-align: right" title="Stock-based compensation award">2,841,533</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB9YizVXdPy2" style="width: 14%; text-align: right" title="Stock-based compensation award">5,869,543</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>RSUs</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzzBwVyqYow8" style="text-align: right" title="Stock-based compensation award">3,477,020</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOR4pvSqWrH9" style="text-align: right" title="Stock-based compensation award">3,544,782</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Shares issued for services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230930__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zg72oyX9peS9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__custom--SharesIssuedForServicesMember_zv1YtgogewH5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock-based compensation award">140,245</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20230101__20230930_zZPPPzy7OAi6" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award">6,318,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930_zVYjj7m7O1Tf" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock-based compensation award">9,554,570</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2023-07-012023-09-30_us-gaap_EmployeeStockOptionMember37226828" decimals="0" unitRef="USD"> 329571 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2022-07-012022-09-30_us-gaap_EmployeeStockOptionMember37226828" decimals="0" unitRef="USD"> 1865297 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2023-07-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember37226828" decimals="0" unitRef="USD"> 1164135 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2022-07-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember37226843" decimals="0" unitRef="USD"> 1190349 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2022-07-012022-09-30_custom_SharesIssuedForServicesMember" decimals="0" unitRef="USD"> 18923 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2023-07-012023-09-30" decimals="0" unitRef="USD"> 1493706 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2022-07-012022-09-30" decimals="0" unitRef="USD"> 3074528 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2023-01-012023-09-30_us-gaap_EmployeeStockOptionMember37226859" decimals="0" unitRef="USD"> 2841533 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember37226859" decimals="0" unitRef="USD"> 5869543 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockUnitsRSUMember37226718" decimals="0" unitRef="USD"> 3477020 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockUnitsRSUMember37226875" decimals="0" unitRef="USD"> 3544782 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2022-01-012022-09-30_custom_SharesIssuedForServicesMember" decimals="0" unitRef="USD"> 140245 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 6318553 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 9554570 </us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 872304 </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2023-01-01to2023-09-30"> P0Y10M13D </us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_80D_eus-gaap--LesseeOperatingLeasesTextBlock_zfO5qPFRK152" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note 6 - </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_824_z5jCoPqWhZQf">LEASES</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a party to a lease for <span id="xdx_90D_eus-gaap--AreaOfLand_iI_usqft_c20230930__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zRgoYKkpORJe" title="Area of land">6,800</span> square feet of space located in Melville, New York (the “Melville Lease”) with respect to its corporate and laboratory operations. The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between $<span id="xdx_907_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230930__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zIrdpyRZx9Ik" title="Rent expense">132,600</span> and $<span id="xdx_90E_eus-gaap--PaymentsForRent_pp0p0_c20230101__20230930__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zuZiLANXhJk" title="Rent expense">149,260</span>. In June 2019, <span id="xdx_908_eus-gaap--LessorOperatingLeaseOptionToExtend_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember_zkhcmXC9k8L5" title="Lease extension description">the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $<span id="xdx_906_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MinimumMember_zKDrSptqaxIe" title="Rent expense">153,748</span> and $<span id="xdx_90E_eus-gaap--PaymentsForRent_pp0p0_c20190601__20190630__srt--StatementGeographicalAxis__custom--MelvilleLeaseMember__srt--RangeAxis__srt--MaximumMember_zf64kb7GZWwj" title="Rent expense">173,060</span>.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was<span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20230930_z8cXDoqXVOKe" title="Weighted average incremental borrowing rate"> 12</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zEKdqfaTgkCg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents net lease cost and other supplemental lease information:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zhF6m0noN9M2" style="display: none">SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20230930_zHTXgQ4gXTTk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220930_zdPPNu5DUcW7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzEnl_znbYMgTb2MJj" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Operating lease cost (cost resulting from lease payments)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">126,021</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">122,349</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_ziUPmfi97rXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net lease cost</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">126,021</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">122,349</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zFyxnQZWVmBk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease – operating cash flows (fixed payments)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">126,021</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">122,349</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingLeaseLiabilityReduction_z23SkaOQUtn8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease – operating cash flows (liability reduction)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">102,921</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">87,945</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current leases – right of use assets</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20230930_zhccCfiAcBK6" style="text-align: right" title="Non-current leases - right of use assets">154,726</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220930_zvOLobczzIH9" style="text-align: right" title="Non-current leases - right of use assets">270,772</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities – operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20230930_zOXSaAO1xEqa" style="text-align: right" title="Current liabilities - operating lease liabilities">156,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220930_zuzst0Jv9Hsc" style="text-align: right" title="Current liabilities - operating lease liabilities">134,031</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current liabilities – operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20230930_zIu058o5vYCc" style="text-align: right" title="Non-current liabilities - operating lease liabilities">42,414</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20220930_z8YbiBJ88apk" style="text-align: right" title="Non-current liabilities - operating lease liabilities">198,724</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_z2xNOYQ5f1Ia" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_znw1NnAIj8Q2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases as of September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zY3yTeILO9Fb" style="display: none">SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230930_zOdqcHh92vJl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzPoB_zPk7aPKuuY2e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Remainder of 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">42,007</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzPoB_znkybT9nZMVl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">173,060</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzPoB_z6ks9DuBnSCk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">215,067</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zwNsgG2L8IV3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,343</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_zRMghcukdnYl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of net future minimum lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">198,724</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_znbCKRzvHV48" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
</us-gaap:LesseeOperatingLeasesTextBlock>
<us-gaap:AreaOfLand contextRef="AsOf2023-09-30_custom_MelvilleLeaseMember" decimals="INF" unitRef="sqft"> 6800 </us-gaap:AreaOfLand>
<us-gaap:PaymentsForRent contextRef="From2023-01-012023-09-30_custom_MelvilleLeaseMember_srt_MinimumMember" decimals="0" unitRef="USD"> 132600 </us-gaap:PaymentsForRent>
<us-gaap:PaymentsForRent contextRef="From2023-01-012023-09-30_custom_MelvilleLeaseMember_srt_MaximumMember" decimals="0" unitRef="USD"> 149260 </us-gaap:PaymentsForRent>
<us-gaap:LessorOperatingLeaseOptionToExtend contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember"> the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between $153,748 and $173,060. </us-gaap:LessorOperatingLeaseOptionToExtend>
<us-gaap:PaymentsForRent contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MinimumMember" decimals="0" unitRef="USD"> 153748 </us-gaap:PaymentsForRent>
<us-gaap:PaymentsForRent contextRef="From2019-06-012019-06-30_custom_MelvilleLeaseMember_srt_MaximumMember" decimals="0" unitRef="USD"> 173060 </us-gaap:PaymentsForRent>
<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2023-09-30" decimals="INF" unitRef="Pure"> 0.12 </us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
<us-gaap:LeaseCostTableTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_zEKdqfaTgkCg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents net lease cost and other supplemental lease information:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zhF6m0noN9M2" style="display: none">SCHEDULE OF NET LEASE COST AND OTHER SUPPLEMENTAL LEASE INFORMATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20230930_zHTXgQ4gXTTk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220930_zdPPNu5DUcW7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Lease cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseCost_maLCzEnl_znbYMgTb2MJj" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Operating lease cost (cost resulting from lease payments)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">126,021</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">122,349</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LeaseCost_iT_pp0p0_mtLCzEnl_ziUPmfi97rXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net lease cost</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">126,021</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">122,349</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zFyxnQZWVmBk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease – operating cash flows (fixed payments)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">126,021</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">122,349</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--OperatingLeaseLiabilityReduction_z23SkaOQUtn8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating lease – operating cash flows (liability reduction)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">102,921</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">87,945</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current leases – right of use assets</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20230930_zhccCfiAcBK6" style="text-align: right" title="Non-current leases - right of use assets">154,726</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20220930_zvOLobczzIH9" style="text-align: right" title="Non-current leases - right of use assets">270,772</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current liabilities – operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20230930_zOXSaAO1xEqa" style="text-align: right" title="Current liabilities - operating lease liabilities">156,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20220930_zuzst0Jv9Hsc" style="text-align: right" title="Current liabilities - operating lease liabilities">134,031</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-current liabilities – operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20230930_zIu058o5vYCc" style="text-align: right" title="Non-current liabilities - operating lease liabilities">42,414</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20220930_z8YbiBJ88apk" style="text-align: right" title="Non-current liabilities - operating lease liabilities">198,724</td><td style="text-align: left"> </td></tr> </table>
</us-gaap:LeaseCostTableTextBlock>
<us-gaap:OperatingLeaseCost contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 126021 </us-gaap:OperatingLeaseCost>
<us-gaap:OperatingLeaseCost contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 122349 </us-gaap:OperatingLeaseCost>
<us-gaap:LeaseCost contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 126021 </us-gaap:LeaseCost>
<us-gaap:LeaseCost contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 122349 </us-gaap:LeaseCost>
<us-gaap:OperatingLeasePayments contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 126021 </us-gaap:OperatingLeasePayments>
<us-gaap:OperatingLeasePayments contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 122349 </us-gaap:OperatingLeasePayments>
<BRTX:OperatingLeaseLiabilityReduction contextRef="From2023-01-01to2023-09-30" decimals="0" unitRef="USD"> 102921 </BRTX:OperatingLeaseLiabilityReduction>
<BRTX:OperatingLeaseLiabilityReduction contextRef="From2022-01-012022-09-30" decimals="0" unitRef="USD"> 87945 </BRTX:OperatingLeaseLiabilityReduction>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 154726 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 270772 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 156310 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 134031 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 42414 </us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD"> 198724 </us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_89D_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_znw1NnAIj8Q2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases as of September 30, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zY3yTeILO9Fb" style="display: none">SCHEDULE OF FUTURE MINIMUM PAYMENTS UNDER NON-CANCELABLE LEASES FOR OPERATING LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230930_zOdqcHh92vJl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzPoB_zPk7aPKuuY2e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Remainder of 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">42,007</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzPoB_znkybT9nZMVl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">173,060</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzPoB_z6ks9DuBnSCk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">215,067</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zwNsgG2L8IV3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,343</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_zRMghcukdnYl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of net future minimum lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">198,724</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 42007 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 173060 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 215067 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 16343 </us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
<us-gaap:OperatingLeaseLiability contextRef="AsOf2023-09-30" decimals="0" unitRef="USD"> 198724 </us-gaap:OperatingLeaseLiability>
<us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-09-30">
<p id="xdx_801_eus-gaap--SubsequentEventsTextBlock_zeczTx1hxN2k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Note 7 – </b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_829_zrkKCz430Ati">SUBSEQUENT EVENTS</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2023, the Company entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (the “Sales Agent”) under which the Company currently has the ability to issue and sell shares of its Common Stock, from time to time, through the Sales Agent, up to an aggregate offering price of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--DemandSalesAgreementMember_zMoO1LWSKZ2f">5,486,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in what is commonly referred to as an “at-the-market” (“ATM”) program. In October 2023, the Company sold an additional <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWPRC4z4DDjb">39,276 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its Common Stock at an average price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20231031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBoFP0lsxls6">2.17 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and raised approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20231001__20231031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUO8WimXMBEe">86,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in gross proceeds under the ATM program.</span></p>
</us-gaap:SubsequentEventsTextBlock>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2023-04-012023-04-30_us-gaap_CommonStockMember_custom_DemandSalesAgreementMember" decimals="0" unitRef="USD"> 5486000 </us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2023-10-012023-10-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" decimals="INF" unitRef="Shares"> 39276 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharesIssuedPricePerShare contextRef="AsOf2023-10-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" decimals="INF" unitRef="USDPShares"> 2.17 </us-gaap:SharesIssuedPricePerShare>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2023-10-012023-10-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" decimals="0" unitRef="USD"> 86000 </us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/15/23  BioRestorative Therapies, Inc.    S-8        11/15/23    5:60K                                    Certilman Balin … LLP/FA


1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/05/23  BioRestorative Therapies, Inc.    8-K:3,9    12/29/22   16:27M                                    Certilman Balin … LLP/FA
Top
Filing Submission 0001493152-23-040483   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 17, 4:47:39.1pm ET